Cipla launches India’s first pneumotach based portable wireless Spirometer, Spirofy

0 34

Cipla Limited, on Wednesday, launched India’s first pneumotach-based portable wireless Spirometer, Spirofy. The announcement, made on World COPD Day, has strengthened its lung leadership position by facilitating early diagnosis for COPD.

With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis and strengthen its position as the lung leader in India. The launch and the product have come up in line with its #LungAttack campaign that endeavors to drive awareness about COPD and encourage early diagnosis.

“Cipla has been steadfastly focused on addressing the world’s growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy® launch aims to help doctors across the country to improve lives of patients through accurate and affordable diagnosis.”

Mr. Umang Vohra, MD and Global CEO, Cipla Limited

Spirofy is an outcome of 5 years of extensive in-house research by Cipla’s Integrated Product Development (IPD) team, and the product aims to transform Obstructive Airway Disease (OAD) diagnosis in India. 

According to the recent press release by Cipla, ‘This advanced device ensures high result accuracy and individual patient safety using Bacterial Viral Filters. Spirofy® is entirely wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians’ flexibility and ease of use. The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone. Cipla will undertake the training of physicians in the interpretation of spirometry results.’

Spirometry is the gold standard for COPD diagnosis; however, the bulky size, complex functionality, and requirement for frequent maintenance are some of the reasons that impacted the widespread acceptance of conventional spirometers by medical practitioners.  As a result, COPD illnesses in India were underdiagnosed or misdiagnosed. COPD is currently the second leading cause of death in India, behind cardiovascular disease, with India accounting for 32% of the global COPD burden.

Leave A Reply

Your email address will not be published.